Capula Management’s Royalty Pharma RPRX Stock Holding History

Capula Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-89,350	Closed	-$2.78M	–	824
2025 Q1	$2.78M	Buy	+89,350	New	+$2.83M	0.02%	171
2024 Q3	–	Sell	-15,470	Closed	-$408K	–	622
2024 Q2	$408K	Buy	+15,470	New	+$429K	﹤0.01%	316
2023 Q3	–	Sell	-15,020	Closed	-$462K	–	645
2023 Q2	$462K	Buy	+15,020	New	+$509K	0.01%	335
2023 Q1	–	Sell	-10,410	Closed	-$411K	–	901
2022 Q4	$411K	Sell	10,410 -13,030	-56%	-$544K	0.01%	620
2022 Q3	$942K	Buy	+23,440	New	+$1M	0.01%	411

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Capula Management's RPRX Position: Q2 2025 in Review

Capula Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 89,350 shares — an estimated $2.78M sold.

Capula Management first reported a position in RPRX in Q3 2022 and held it in 5 quarters. The position peaked at $2.78M in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Capula Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Capula Management sold 89,350 Royalty Pharma shares in Q2 2025, an estimated $2.78M.
Capula Management first reported a position in Royalty Pharma in Q3 2022 and held it in 5 quarters.
Capula Management's Royalty Pharma position peaked at $2.78M in Q1 2025.
454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.